(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s ...

UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a new "next generation" inhaler with a propellant that reduces Global ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for 50% of the company’s total revenue by 2030.

which won approval in Japan a few months ago and is marketed there as Breztri Aerosphere. GlaxoSmithKline won approval for a three-drug COPD inhaler, Trelegy Ellipta, in 2017. 3D medical animation ...

AstraZeneca’s other drugs, Fasenra, Calquence, Breztri and newer products, asthma drug Tezspire, breast cancer drug Truqap and lupus drug Saphnelo (anifrolumab) are likely to have contributed to ...

AstraZeneca’s recent presentation at the ... for half of the company’s total revenue by 2030. Key drivers include Breztri Aerosphere (budesonide, formoterol fumarate, and glycopyrrolate ...